Immunomedics (IMMU) - moderated | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Immunomedics (IMMU) - moderated

An SI Board Since September 2006

Posts	SubjectMarks	Bans	Symbol
63388	357	15	IMMU

Emcee: idahoranch1	Type: Moderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
61218	SAVA is truly off the radar. A totally misguided article from IBD touts Biogen	scorman1	1	10/13/2022
61217	SAVA allowing an Open Label Phase III for anyone completing their blinded P3 tri	Davidoff	1	10/13/2022
61216	An investor from Sava Discord (SmileyGirl) reached out to Dr. Espay and he repli	ghettogoulash	-	10/12/2022
61215	One of the hallmarks of Alzheimer's disease is low levels of the protein AB	ghettogoulash	-	10/12/2022
61214	Merck and Moderna to cooperate in personalized MRNA cancer vaccines. If this te	kdd999	1	10/12/2022
61213	The AADI management and board looks like an IMMU alumni club. Even Behzad shows	Renmanco	2	10/12/2022
61212	“… and I might seriously consider counseling...”. Or perhaps Simufilam!	jargonweary	1	10/12/2022
61211	AADI poster presentation: Aadi Bioscience Announces Improved Anti-Tumor Activit	erickerickson	1	10/12/2022
61210	Doc's downfall, so to speak, was enabled by his constant share dilution, whi	allatwwk	4	10/11/2022
61209	The key difference is that IMMU had some important institutional investors who e	jargonweary	4	10/11/2022
61208	Agree. IMMU science was good, management was bad, then with the help of proxy f	Davidoff	2	10/11/2022
61207	re: GILD and Trodelvy. 'Sales of the drug rose 90% to $305 million in the f	erickerickson	6	10/11/2022
61206	I think this is Q2 data, so not new news. But interesting.	bodish	-	10/11/2022
61205	Not sure if any of this is news but happened to see it. The Vanguard Group, Inc	sysiphus	3	10/11/2022
61204	Gilead's Trodelvy gets FDA priority review for expanded use in breast cancer	Davidoff	8	10/11/2022
61203	Annovis trial data publication: Buntanetap phase 2a trial It is promising an th	scorman1	-	10/11/2022
61202	SRPT presents some new data: Sarepta Therapeutics Presents New Data from its Ge	erickerickson	2	10/7/2022
61201	"Caregiver freedom" in itself is invaluable. In each of these four pat	ghettogoulash	-	10/7/2022
61200	The difference is with Calvin and Martha, there was no other data to support eff	ghettogoulash	-	10/6/2022
61199	SAVA springer bit: Reminds me Calvin and Martha, feel-good and encouraging, but	erickerickson	2	10/6/2022
61198	So just for yucks I looked to see whether SAVA had any news lately. The usual fl	erickerickson	-	10/6/2022
61197	SAVA: this Springer video is worth watching. you can start at the 6:25 mark ...	plhky3465	1	10/6/2022
61196	I should have said, "Too good to be true, especially when the short sellers	ghettogoulash	-	10/4/2022
61195	Dr. Robinson actually did comment on the 100-patient readout at 12 months. To me	ghettogoulash	-	10/4/2022
61194	No matter what you can count on ol’ Joe to spread his heavily tattooed arms out	jargonweary	1	10/4/2022

Go to reply# or date (mm/dd/yy):